ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide (ProA)

This is a Phase 4, multi-center, single arm, open-label clinical study to evaluate whether participants with mHSPC treated with apalutamide will benefit from the 4A ProActive Management Model.

The study will include a Screening Period of up to 14 days before assignment on Day 1 to establish study eligibility. Participants will get 4A ProActive Management according to the protocol .

As the background disease treatment, participants will received apalutamide according to local label (240 mg, 4 × 60 mg tablets, orally once daily with or without food) with duration of at least 6 months. Participants will have a Safety Follow-Up Visit within 30 days after the Visit 7.

Participants will be monitored for safety, starting from the time of signing the informed consent until 30 days after the Visit 7. AEs including laboratory AEs will be graded and summarized using Version 5.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events.

Study Overview

• Status: Enrolling by invitation
• Conditions: Prostate Cancer (Adenocarcinoma)
• Intervention / Treatment: Behavioral: The 4A ProActive Management Model

• Study Type: Observational
• Enrollment (Estimated): 94

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Affiliated Cancer Hospital of Sun Yat-sen University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Participants with mHSPC treated with apalutamide

Description

Inclusion Criteria:

1. Participant must be a man ≥ 18 years of age, at the time of signing the informed consent.
2. Participants who are diagnosed of prostate adenocarcinoma as confirmed by the Investigator and intend to be prescribed by apalutamide.
3. Androgen deprivation therapy (ie, medical or surgical castration) must have been started less than 3 months prior to screening.
4. Participant will be initiated with apalutamide and androgen deprivation therapy.
5. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (eg, wheelchair-bound due to prior spinal cord injury) and not related to prostate cancer or associated therapy.
6. Be able to swallow whole apalutamide tablets.

7. A participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for at least 3 months after receiving the last dose of apalutamide.

   If the participant's partner is a person of childbearing potential, the participant must use condoms (with or without spermicide) and the sexual partner of the participant must also be practicing a highly effective method of contraception where conception is possible. A vasectomized participant must still use a condom (with or without spermicide) and the partner is also required to use a highly effective method of contraception where conception is possible.

8. A participant must agree not to donate sperm for the purposes of reproduction during the study and for at least 3 months after receiving the last dose of apalutamide. If applicable, participants should consider preservation of sperm prior to study treatment as anti cancer treatments may impair fertility.
9. A participant must agree not to plan to conceive a child while enrolled in this study or within 3 months after the last dose of apalutamide.
10. Participants are capable of giving signed informed consent.

Exclusion Criteria:

1. Pathological findings consistent with small cell, ductal or neuroendocrine carcinoma of the prostate.

2. Participant has active (new or progressive) brain metastases for whom the treating physician determines that central nervous system (CNS) specific treatment is required immediately or during the first cycle of therapy. Lymph nodes as only sites of metastases.

   Those with active (new or progressive) brain metastases for whom the treating physician determines that CNS specific treatment is not required immediately or during the first cycle of therapy are eligible for inclusion.

3. Visceral (ie, liver or lung) metastases as only sites of metastases.

4. Current evidence of any of the following:

   1. Any of the following within 6 months prior to first dose of apalutamide: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease.
   2. Gastrointestinal disorder affecting absorption.
   3. Active infection requiring systemic therapy such as human immunodeficiency virus.
   4. Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding disorders secondary to hepatic dysfunction
5. History of seizure or known condition that has been determined to significantly predispose to seizure per Investigator (including, but not limited to, loss of consciousness within 1 year prior to screening, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).
6. Participant have known allergies, hypersensitivity, or intolerance to apalutamide or its excipients (please refer to Investigator's Brochure).
7. Prior novel hormone therapy or chemotherapy.
8. Treatment with drugs known to lower the seizure threshold within 4 weeks prior to enrollment.
9. Current or prior treatment with anti-epileptic medications for the treatment of seizures.
10. Administration of other investigational therapeutic agents, blood product support, growth factor support or invasive surgical procedure (not including surgical castration) ≤ 28 days prior to the first dose of apalutamide or currently enrolled in an investigational study.
11. Any condition or situation that in the opinion of the Investigator, would preclude participation in the study.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the change of FACT-P total score after 6 months from baseline.The Fact-P is the Functional Assessment of Cancer Therapy-Prostate.The score range is 0-156 points. The higher the score is, the higher the quality of life of the subjects is.	The Fact-P is the Functional Assessment of Cancer Therapy-Prostate.The score range is 0-156 points. The FACT-P scale has a uniform calculation formula, which is obtained by summing up the scores of each subscale.FACT-P Total score=(PWB score)+ (SWB score) +(EWB score) + (FWB score) + (PCS score)。The higher the score is, the higher the quality of life of the subjects is.	6 months

Collaborators and Investigators

• Sponsor: Yonghong Li

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2025
• Primary Completion (Estimated): January 30, 2026
• Study Completion (Estimated): August 30, 2026

Study Registration Dates

• First Submitted: February 20, 2025
• First Submitted That Met QC Criteria: March 5, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 5, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms
• Other Study ID Numbers: 2024-FXY-317

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No